Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer

Oncology
Salah-Eddin Al-BatranElke Jager

Abstract

The aim of this study was to assess whether the reduction in the total dose of pegylated liposomal doxorubicin (PLD) per cycle from 50 mg/m(2) every 4 weeks to 40 mg/m(2) every 4 weeks can effectively lower the incidence of treatment-related palmar-plantar erythrodysesthesia (PPE) and mucositis. Patients received PLD 40 mg/m(2) every 4 weeks, and were evaluated for toxicity prior to each treatment and for response every 8 weeks. All patients were previously treated with at least one chemotherapy regimen for metastatic disease, and 72% of the patients had a prior exposure to an anthracycline. Forty-six evaluable patients received a median of four PLD cycles, with a median dose intensity of 10 mg/m(2)/week and a median cumulative dose of 160 mg/m(2). No National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 PPE was observed in these patients. NCI-CTC grade 3 or 4 mucositis occurred in 4.3% of patients, only. Response rates and survival results observed here were comparable to those observed with PLD 50 mg/m(2) every 4 weeks in a matched patient population. However, patients treated with PLD 40 mg/m(2) every 4 weeks experienced less PPE and mucositis and required clearly less dose reductions and treatment delays...Continue Reading

References

Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R RansonA Howell
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
May 2, 2001·Gynecologic Oncology·S M CamposM V Seiden
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
May 13, 2003·Clinical Pharmacokinetics·Alberto GabizonYechezkel Barenholz
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Jan 13, 2004·Clinical Breast Cancer·Joyce A O'Shaughnessy
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E R O'BrienUNKNOWN CAELYX Breast Cancer Study Group
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan M KellerCraig Tendler
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo

❮ Previous
Next ❯

Citations

Jan 22, 2009·Cancer Chemotherapy and Pharmacology·Jalid SehouliUNKNOWN North-Eastern German Society of Gynecological Oncology
Sep 29, 2009·Cancer Chemotherapy and Pharmacology·Elodie VauléonPierre Kerbrat
Mar 2, 2011·Chinese Journal of Integrative Medicine·Dong Xue, Ping-Ping Li
Apr 12, 2011·Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology·Tyler G St DenisMichael R Hamblin
Dec 6, 2012·Experimental Hematology & Oncology·Shamudheen M RafiyathDelong Liu
Jan 21, 2014·Cancer Chemotherapy and Pharmacology·Milena GusellaFelice Pasini
Jul 13, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C Martín Sabroso, A I Torres-Suárez
Jan 30, 2014·Journal of Geriatric Oncology·Umberto BassoSilvio Monfardini
Mar 28, 2008·Expert Review of Anticancer Therapy·Alessandro M MinisiniFabio Puglisi
Mar 21, 2008·Journal of Pharmaceutical Sciences·Daryl C DrummondDmitri B Kirpotin
Jun 6, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C FalandryG Freyer
Sep 30, 2014·Molecular Pharmaceutics·Jianqin LuSong Li
May 21, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette DegenRalf Gutzmer
Mar 12, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roger von MoosAxel Hauschild
Mar 2, 2010·Oncology Nursing Forum·Karen K Swenson, Elaine M Bell
Oct 27, 2015·Archives of Gynecology and Obstetrics·Christine MayerJoachim Rom
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maureen E TrudeauJean-Francois Pouliot
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Mario ScartozziStefano Cascinu
Jul 9, 2014·Bioscience of Microbiota, Food and Health·Soma NozakaYasushi Morinaga
Jun 28, 2020·European Journal of Hospital Pharmacy. Science and Practice·Yao ZhuXiaoling Zheng
Mar 5, 2020·Therapeutic Advances in Medical Oncology·Fausto Meriggi, Alberto Zaniboni
Jan 8, 2020·International Journal of Women's Dermatology·Michelle N FerreiraJonathan S Leventhal
Sep 22, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ayman ShafeiMahmoud Ellithy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.